Stocks and Investing
Stocks and Investing
Fri, May 7, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, May 6, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Coleman Upgraded (CC) to Strong Buy and Held Target at $40 on, May 6th, 2021
David Coleman of Argus Research, Upgraded "The Chemours Company" (CC) to Strong Buy and Held Target at $40 on, May 6th, 2021.
David has made no other calls on CC in the last 4 months.
There are 2 other peers that have a rating on CC. Out of the 2 peers that are also analyzing CC, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vincent Andrews of "Morgan Stanley" Maintained at Hold with Increased Target to $30 on, Tuesday, February 16th, 2021
This is the rating of the analyst that currently disagrees with David
- Arun Viswanathan of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $35 on, Friday, January 8th, 2021
Contributing Sources